Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Atai Life SciencesN. V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression.
The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.
In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder.
Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression.
ATAI Life SciencesN. V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 5, 24 | -0.16 Increased by +42.86% | -0.16 |
| Aug 6, 24 | -0.36 Decreased by -71.43% | -0.16 Decreased by -125.00% |
| May 15, 24 | -0.17 Increased by +19.05% | -0.18 Increased by +5.56% |
| Mar 28, 24 | -0.12 Increased by +57.14% | -0.16 Increased by +25.00% |
| Nov 14, 23 | -0.28 Decreased by -27.27% | -0.20 Decreased by -40.00% |
| Aug 10, 23 | -0.21 Increased by +12.50% | -0.21 |
| May 11, 23 | -0.21 Increased by +12.50% | -0.21 |
| Mar 24, 23 | -0.28 Increased by +54.84% | -0.23 Decreased by -21.74% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 40.00 K Decreased by -54.02% | -26.29 M Decreased by -159.41% | Decreased by -65.72 K% Decreased by -229.22% |
| Jun 30, 24 | 273.00 K Increased by +58.72% | -57.31 M Decreased by -73.45% | Decreased by -20.99 K% Decreased by -9.28% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -26.71 M Increased by +19.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 18.00 K Decreased by -52.63% | -18.29 M Increased by +59.64% | Decreased by -101.62 K% Increased by +14.80% |
| Sep 30, 23 | 87.00 K Increased by +262.50% | 44.24 M Increased by +232.99% | Increased by +50.86 K% Increased by +136.69% |
| Jun 30, 23 | 172.00 K Increased by +1.18% | -33.04 M Decreased by -7.08% | Decreased by -19.21 K% Decreased by -5.84% |
| Mar 31, 23 | 37.00 K Increased by +N/A% | -33.32 M Decreased by -4.25% | Decreased by -90.06 K% Decreased by N/A% |
| Dec 31, 22 | 38.00 K Decreased by -83.48% | -45.32 M Increased by +49.00% | Decreased by -119.27 K% Decreased by -208.66% |